Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases
Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases
复制标题
DOI：
10.1200/jco.2012.45.2854
复制
发表时间：
2012-12-20
影响因子：
45.3
通讯作者：
Vauthey, Jean-Nicolas
中科院分区：
文献类型：
--
作者：
Shindoh, Junichi;Loyer, Evelyne M.;Vauthey, Jean-Nicolas
目的本研究的目的是确认术前化疗的最佳形态反应对结直肠癌肝转移（CLM）切除术前接受化疗或不使用贝伐单抗的患者的预后价值，并确定最佳形态反应的预测因素。患者和方法该研究包括209例患者，术前化疗后采用奥沙利铂或伊立替康为基础的方案，联合或不联合贝伐单抗进行CLM切除。根据形态学反应标准将放射反应分为最佳或次优。确定总生存期（OS），并在多变量分析中确定与最佳反应相关的预后因素。结果47%接受贝伐单抗治疗的患者和12%未接受贝伐单抗治疗的患者出现了最佳的形态学反应
PurposeThe purposes of this study were to confirm the prognostic value of an optimal morphologic response to preoperative chemotherapy in patients undergoing chemotherapy with or without bevacizumab before resection of colorectal liver metastases (CLM) and to identify predictors of the optimal morphologic response.Patients and MethodsThe study included 209 patients who underwent resection of CLM after preoperative chemotherapy with oxaliplatin- or irinotecan-based regimens with or without bevacizumab. Radiologic responses were classified as optimal or suboptimal according to the morphologic response criteria. Overall survival (OS) was determined, and prognostic factors associated with an optimal response were identified in multivariate analysis.ResultsAn optimal morphologic response was observed in 47% of patients treated with bevacizumab and 12% of patients treated without bevacizumab (P